Skip to content


  • Poster presentation
  • Open Access

The Rainbow Cohort: saquinavir/r is effective and well tolerated in antiretroviral therapy (ART)-naïve patients – 48-week results from Germany

  • 1,
  • 2,
  • 3,
  • 4,
  • 5,
  • 3,
  • 6,
  • 7,
  • 8,
  • 9,
  • 10,
  • 11 and
  • 11
Journal of the International AIDS Society200811 (Suppl 1) :P13

  • Published:


  • Viral Load
  • Saquinavir
  • Tablet Formulation
  • Virologic Failure
  • Baseline Viral Load

Purpose of the study

The aim of the Rainbow Cohort is to assess the tolerability and efficacy of initiating treatment with, or switching treatment to saquinavir (SQV) 500 mg film-coated tablet formulation. We present the final 48-week subgroup analysis of antiretroviral therapy (ART)-naïve patients.


Multicenter, prospective, open-label, observational cohort study. Tolerability assessments include changes in liver enzymes and lipid levels from baseline to week 48, efficacy assessments include changes in viral load (VL) and CD4 count.

Summary of results

48-week analysis of n = 275 ART-naïve patients. Baseline characteristics: 83% male, median age 39 years, median time since HIV diagnosis 1 year (IQR 0; 4), median baseline viral load (VL) 115,781 HIV-RNA cp/mL (IQR 35,375; 347,450), median CD4 count 200 cells/mm3 (IQR 89; 297). Antiretroviral regimen included SQV/r plus tenofovir/emtricitabine, zidovudine/lamivudine or abacavir/lamivudine in 49%, 19% and 7% of patients, respectively.

In week 48, the proportion of patients achieving a VL <50 cp/mL was 75.3% (OT analysis) and 67.3% (ITT, LOCF analysis), respectively. Median increase in CD4 cell count was + 174 cells/mm3 (IQR 86; 265). Median changes in triglycerides, total cholesterol, ALT, AST and γ-GT were +17 mg/dL (IQR -27; 71), +27 mg/dL (4; 55), -6 U/L (-26; 1), -1 U/L (-9; 6), -2 U/L (-25; 6), respectively. SQV treatment was stopped in 21% of the patients (3% due to side-effects, 1% due to virologic failure). See Figure 1.
Figure 1
Figure 1

Proportion of patients below the detection limit during 48 weeks after start of a SQV/r containing antiretroviral therapy.


These data confirm that SQV/r is effective and well tolerated in ART-naïve patients in the real-life clinical setting. The results of this observational cohort of treatment with the 500 mg tablet formulation of SQV are consistent with high efficacy and tolerability results seen in controlled studies with SQV/r.

Authors’ Affiliations

Praxenzentrum Blondelstrasse (PZB), Aachen, Germany
Klinikum der Johann-Wolfgang-Goethe-Universitaet, Frankfurt, Germany
Infektiologikum Frankfurt, Frankfurt a. M., Germany
Institut fuer Interdisziplinaere Medizin (ifi), Hamburg, Germany
Praxis Dres. S. Dupke/A. Carganico/A. Baumgarten, Berlin, Germany
Infektionsmedizinisches Centrum Hamburg (ICH), Hamburg, Germany
HIV Research and Clinical Care Centre Munich, Munich, Germany
MVZ-Aerzteforum Seestrasse Dres. C. Mayr/PD W. Schmidt, Berlin, Germany
Praxis Dres. F.A. Mosthaf/M. Procaccianti/K. Zutavern-Bechtold, Karlsruhe, Germany
MUC Research, Munich, Germany
Roche Pharma AG, Grenzach-Wyhlen, Germany


© Knechten et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.